Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.62 |
| ▸ | HTT | P42858 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | NOS1 | P29475 | 2/20 | 0.57 |
| ▸ | NOS3 | P29474 | 1/20 | 0.57 |
| ▸ | NOS2 | P35228 | 1/20 | 0.57 |
| ▸ | SLC11A2 | P49281 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812696 | 0.86 | IDO1 (0.74) | IDO1HTTSMN1; SMN2TAAR1LMNA | |
| Bromide SCHEMBL2810146 | 0.84 | IDO1 (0.71) | IDO1HTTSMN1; SMN2TAAR1LMNA | |
| Hydrochloric Acid SCHEMBL22263112 | 0.84 | IDO1 (0.75) | IDO1HTTSMN1; SMN2TAAR1LMNA | |
| SCHEMBL3679465 | 0.80 | IDO1 (0.67) | IDO1HTTSMN1; SMN2TAAR1LMNA | |
| SCHEMBL3693822 | 0.79 | IDO1 (0.61) | IDO1HTTSMN1; SMN2TAAR1LMNA | |
| Bromide SCHEMBL4437731 | 0.78 | IDO1 (0.59) | IDO1HTTSMN1; SMN2TAAR1LMNA | |
| SCHEMBL3770841 | 0.78 | IDO1 (0.51) | IDO1HTTSMN1; SMN2TAAR1LMNA | |
| SCHEMBL3690551 | 0.78 | HTT (0.65) | IDO1HTTSMN1; SMN2TAAR1LMNA | |
| SCHEMBL13007579 | 0.77 | IDO1 (1.00) | IDO1HTTSMN1; SMN2TAAR1LMNA | |
| SCHEMBL12433171 | 0.77 | IDO1 (0.62) | IDO1HTTSMN1; SMN2TAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737815-B1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-7981907-B2 | Thio-substituted biarylmethanesulfinyl derivatives | CEPHALON, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090062284-A1 | Thio-Substituted Biarylmethanesulfinyl Derivatives | CEPHALON, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-7449481-B2 | e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue | CEPHALON, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| CN-1997628-A | Sulfur-substituted diarylmethanesulfinyl derivatives | CEPHALON INC (US) | 2007-07-11 | — | — | CN | disclosed |
| EP-1737815-A1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON, INC. (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20050245747-A1 | e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue | CEPHALON, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005100308-A1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1586559-A1 | Biaryl-methanethio-, -sulphinyl- and sulphonyl derivatives | CEPHALON, INC. (US) | 2005-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062284-A1 | Thio-Substituted Biarylmethanesulfinyl Derivatives | AANAT, SNCA, NAT1 | IDO1 334/4885HTT 373/4885SMN1; SMN2 685/4885 |
| US-20050245747-A1 | e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue | TPH2, TPH1, AANAT | IDO1 130/4885HTT 235/4885SMN1; SMN2 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.